Business
Bone Biologics Effects 1-for-30 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces
About this update from Bone Biologics Corp
[{"type":"text","content":" BURLINGTON, Mass.--(BUSINESS WIRE)--\nBone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on June 7, 2023. Bone Biologics’ common stock and warrants will continue to trade on Nasdaq under the symbols \"BBLG\" and “BBLGW”, respectively\n\n\nAs a result of the reverse stock split, each 30 pre-split shares of common stock or warrant outstanding were automatically combined and converted into 1 issued and outstanding share of common stock or warrant. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Any fractional share resulting from the reverse stock split has been rounded up to the nearest whole share.\n\n\nStockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Equiniti Trust (EQ). Please call EQ Shareowner Services at 866-877-6270 or 651-306-3000 with any questions Monday through Friday from 7:00 a.m. to 7:00 p.m. Central time.\n\n\nFor additional information regarding the reverse stock split, please refer to Bone Biologics’ Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 6, 2023.\n\n\nAbout Bone Biologics\n\n\nBone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, which build on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.\n\n\nForward-looking Statements\n\n\nCertain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks...